Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | ERN1 | O75460 | 4/20 | 0.50 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.46 |
| ▸ | ABAT | P80404 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16838210 | 0.85 | ERN1 (0.56) | ALDH1A1CYP3A4ERN1XDHALDH5A1 | |
| SCHEMBL1607530 | 0.83 | ERN1 (0.55) | ALDH1A1CYP3A4ERN1TSHRMAPK1 | |
| SCHEMBL537580 | 0.83 | VCAM1 (0.55) | ALDH1A1CYP3A4ERN1VCAM1TSHR | |
| SCHEMBL68172 | 0.81 | ALDH1A1 (0.71) | ALDH1A1CYP3A4VCAM1TSHRMAPK1 | |
| SCHEMBL9789906 | 0.79 | VCAM1 (0.55) | ALDH1A1CYP3A4ERN1VCAM1TSHR | |
| SCHEMBL5583374 | 0.79 | VCAM1 (0.55) | ALDH1A1CYP3A4ERN1VCAM1TSHR | |
| SCHEMBL16838200 | 0.79 | ERN1 (0.55) | ALDH1A1CYP3A4ERN1XDHALDH5A1 | |
| SCHEMBL5642359 | 0.79 | ALDH1A1 (0.63) | ALDH1A1CYP3A4VCAM1TSHRMAPK1 | |
| SCHEMBL8767757 | 0.79 | ALDH1A1 (0.63) | ALDH1A1CYP3A4VCAM1TSHRMAPK1 | |
| SCHEMBL25145164 | 0.79 | VCAM1 (0.50) | ALDH1A1CYP3A4ERN1VCAM1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026086794-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE THEREOF | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2026-04-30 | — | — | WO | disclosed |
| EP-1807440-B1 | NOVOBIOCIN ANALOGUES AS ANTICANCER AGENTS | UNIV KANSAS (US) | 2020-02-19 | — | — | EP | disclosed |
| EP-2438078-B1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | UNIV KANSAS (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2438078-B1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | UNIV KANSAS (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9120774-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120774-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120774-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2015-09-01 | — | — | US | disclosed |
| EP-2231619-B1 | INHIBITORS OF STEAROYL-COA DESATURASE | HOFFMANN LA ROCHE (CH) | 2014-11-26 | — | — | EP | disclosed |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-04 | — | — | US | disclosed |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-04 | — | — | US | disclosed |
| EP-0159962-A2 | Fibre-reactive chromium or cobalt complexes, their preparation and their use | CIBA-GEIGY AG (CH) | 1985-10-30 | — | — | EP | disclosed |
| EP-0156768-A2 | Process for the preparation of 1:2 chromium complex dyes | CIBA-GEIGY AG (CH) | 1985-10-02 | — | — | EP | disclosed |
| EP-0144776-A2 | Fibre-reactive chromium complexes, their preparation and their use | CIBA-GEIGY AG (CH) | 1985-06-19 | — | — | EP | disclosed |
| EP-0142104-A2 | Fibre-reactive chromium complexes, their preparation and their use | CIBA-GEIGY AG (CH) | 1985-05-22 | — | — | EP | disclosed |
| EP-0141416-A2 | Fibre-reactive chromium complexes, their preparation and their use | CIBA-GEIGY AG (CH) | 1985-05-15 | — | — | EP | disclosed |
| US-4436659-A | DYEING POLYAMIDS, AZO DYES | CIBA-GEIGY CORPORATION (US) | 1984-03-13 | — | — | US | disclosed |
| US-4318849-A | COPPER, NICKEL, CHROMIUM OR COBALT COMPLEXES OF AZO OR AZO-METHINE DYES | CIBA-GEIGY CORPORATION (US) | 1982-03-09 | — | — | US | disclosed |
| US-4219473-A | Substituted unsymmetrical azo, azomethine 1:2 chromium complexes | CIBA-GEIGY CORPORATION (US) | 1980-08-26 | — | — | US | disclosed |
| US-4215042-A | PRINTING AND DYEING OF POLYAMIDES; COLORFASTNESS | CIBA-GEIGY CORPORATION (US) | 1980-07-29 | — | — | US | disclosed |
| US-3978037-A | POLYAMIDES | CIBA-GEIGY CORPORATION (US) | 1976-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | HSP90AB1, HSP90AB2P, HSP90B1 | ALDH1A1 3066/4885CYP3A4 3151/4885ERN1 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.